MX2023002377A - Vacuna contra el citomegalovirus humano. - Google Patents
Vacuna contra el citomegalovirus humano.Info
- Publication number
- MX2023002377A MX2023002377A MX2023002377A MX2023002377A MX2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A
- Authority
- MX
- Mexico
- Prior art keywords
- human cytomegalovirus
- cytomegalovirus vaccine
- vaccine
- hcmv
- antigen
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108700021021 mRNA Vaccine Proteins 0.000 abstract 1
- 229940126582 mRNA vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070134P | 2020-08-25 | 2020-08-25 | |
| US202063079421P | 2020-09-16 | 2020-09-16 | |
| US202163136117P | 2021-01-11 | 2021-01-11 | |
| PCT/US2021/047541 WO2022046898A1 (en) | 2020-08-25 | 2021-08-25 | Human cytomegalovirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002377A true MX2023002377A (es) | 2023-05-22 |
Family
ID=80353887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002377A MX2023002377A (es) | 2020-08-25 | 2021-08-25 | Vacuna contra el citomegalovirus humano. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220401551A1 (https=) |
| EP (1) | EP4204001A4 (https=) |
| JP (1) | JP7844442B2 (https=) |
| KR (1) | KR20230057403A (https=) |
| CN (1) | CN116234570A (https=) |
| AU (1) | AU2021331064A1 (https=) |
| BR (1) | BR112023003009A2 (https=) |
| CA (1) | CA3193042A1 (https=) |
| IL (1) | IL300739A (https=) |
| MX (1) | MX2023002377A (https=) |
| TW (1) | TW202228771A (https=) |
| WO (1) | WO2022046898A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| WO2023212696A1 (en) | 2022-04-29 | 2023-11-02 | Modernatx, Inc. | Lyophilized human cytomegalovirus vaccines |
| AU2023427858A1 (en) * | 2023-02-03 | 2025-05-15 | Vernagen, LLC | Respiratory syncytial virus mrna vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130164289A1 (en) * | 2010-09-09 | 2013-06-27 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2018151816A1 (en) * | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| EP3713601A4 (en) * | 2017-11-21 | 2022-03-09 | Modernatx, Inc. | VACCINES AGAINST EPSTEIN-BARR VIRUS |
| CA3154082A1 (en) * | 2019-09-11 | 2021-03-18 | Modernatx, Inc. | Human cytomegalovirus vaccine |
-
2021
- 2021-08-25 MX MX2023002377A patent/MX2023002377A/es unknown
- 2021-08-25 KR KR1020237009798A patent/KR20230057403A/ko not_active Withdrawn
- 2021-08-25 BR BR112023003009A patent/BR112023003009A2/pt not_active Application Discontinuation
- 2021-08-25 CN CN202180052553.XA patent/CN116234570A/zh active Pending
- 2021-08-25 WO PCT/US2021/047541 patent/WO2022046898A1/en not_active Ceased
- 2021-08-25 AU AU2021331064A patent/AU2021331064A1/en not_active Abandoned
- 2021-08-25 TW TW110131517A patent/TW202228771A/zh unknown
- 2021-08-25 JP JP2023513508A patent/JP7844442B2/ja active Active
- 2021-08-25 CA CA3193042A patent/CA3193042A1/en active Pending
- 2021-08-25 IL IL300739A patent/IL300739A/en unknown
- 2021-08-25 EP EP21862650.5A patent/EP4204001A4/en active Pending
-
2022
- 2022-06-14 US US17/840,478 patent/US20220401551A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN116234570A (zh) | 2023-06-06 |
| CA3193042A1 (en) | 2022-03-03 |
| JP2023540476A (ja) | 2023-09-25 |
| WO2022046898A1 (en) | 2022-03-03 |
| EP4204001A1 (en) | 2023-07-05 |
| JP7844442B2 (ja) | 2026-04-13 |
| IL300739A (en) | 2023-04-01 |
| BR112023003009A2 (pt) | 2023-04-25 |
| KR20230057403A (ko) | 2023-04-28 |
| TW202228771A (zh) | 2022-08-01 |
| AU2021331064A1 (en) | 2023-03-16 |
| EP4204001A4 (en) | 2025-04-16 |
| US20220401551A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002377A (es) | Vacuna contra el citomegalovirus humano. | |
| WO2011063336A3 (en) | Secondary site of antigen stimulation for therapeutic vaccination | |
| MX2020007675A (es) | Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante. | |
| WO2009025770A3 (en) | A heterologous prime-boost immunization regimen | |
| MX2020012144A (es) | Composicion de vacuna. | |
| MX363529B (es) | Vesículas de membrana externa. | |
| MX345704B (es) | Vacuna bovinas y métodos. | |
| WO2017096341A3 (en) | Adenovirus-vectored multivalent vaccine | |
| MY190866A (en) | Novel mucosal adjuvants and delivery systems | |
| CO6561819A2 (es) | Vectores para vacunas y método para potenciar respuestas inmunes | |
| MX355501B (es) | Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. | |
| MX2013013228A (es) | Particulas similares a virus y proceso para prepararlas. | |
| NZ715459A (en) | A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same | |
| WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
| PH12014501795B1 (en) | Rotavirus subunit vaccines and methods of making and use thereof | |
| PH12016502529A1 (en) | Influenza vaccine nasal vaccination system | |
| WO2013033496A3 (en) | Laser adjuvants for enhancing immune response | |
| EP3908315A4 (en) | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION AND ENHANCING VACCINE PRODUCTION | |
| MX2015014005A (es) | Complejo inmunogenico para vacunacion y metodo de obtencion. | |
| BR112016001686A2 (pt) | Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição | |
| PL2844759T3 (pl) | Szczepienie z zastosowaniem rekombinowanych drożdży poprzez wywołanie ochronnej humoralnej odpowiedzi odpornościowej przeciwko określonym antygenom | |
| PH12022550939A1 (en) | Chikungunya virus-like particle vaccine and methods of using the same | |
| WO2012103510A8 (en) | Advanced prime and boost vacinne | |
| EP4509185A3 (en) | Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans | |
| PH12013502265A1 (en) | Recombinant vaccine against prrs in a viral vector |